| Summary: | In rheumatic diseases, advances in biological molecular-targeted therapies have brought remarkable progress in treatment, but the molecular and clinical heterogeneity of the diseases can often pose a treatment challenge. In psoriatic arthritis, each patient exhibits various symptoms, and some may be resistant to treatment. It is difficult to improve all of these various symptoms simultaneously with the use of limited drugs. Therefore, precision medicine is an urgent concern that is required to overcome this problem. However, few studies focus on the precision medicine in rheumatic disease including psoriatic arthritis. We explored the potential of precision medicine in which patients with psoriatic arthritis are stratified by lymphocyte flow cytometry to select specific biologics. Selecting specific biologics according to different immunophenotypes of peripheral blood lymphocytes in psoriatic arthritis was shown to produce high therapeutic responses; in other words, the potential of precision medicine was suggested. The peripheral blood lymphocyte analysis can be applied to many other rheumatic diseases presenting various clinical features, such as spondyloarthritis and systemic lupus erythematous. We should shed light on the precision medicine not only in the psoriatic arthritis also in the other rheumatic disease.
|
|---|